-
Mashup Score: 1National Study Reveals Recovery Hurdles for Children Following COVID-19 Hospitalization - 2 month(s) ago
image: Dr. Beth Slomine, co-director of the Brain Injury Clinical Research Center at Kennedy Krieger and assistant vice president of psychology is one of the lead authors in this study. view more Credit: Kennedy Krieger Institute BALTIMORE, February 26, 2024— New research is showing just how difficult recovery is for children who are hospitalized due to COVID-19. Trailblazing data from a national multicenter survey shows that up to one-third of children did not fully recover and experienced persistent symptoms from 1 to 2 years after release from the hospital. The research, published in Frontiers in Pediatrics, found that 30% of parents (23 out of 79) reported that their child had not recovered from COVID-19 and/or multisystem inflammatory syndrome in children (MIS-C), a rare but serious complication that can occur after COVID-19. Children who had not recovered were more likely to have symptoms that were new or persisted after hospital discharge. The majority (87%) of these children h
Source: reachmd.comCategories: General Medicine News, Critical CareTweet
-
Mashup Score: 0
The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.
Source: reachmd.comCategories: Hem/Oncs, Latest HeadlinesTweet-
My discussion w Tara Mitchell, MD @PennCancer on adjuvant #immunotherapy for stage IIB/C #melanoma. Important all patients are offered this important therapy in the context of multi-disciplinary & individualized decision making of pros/cons! @ReachMD #CME https://t.co/BE3YWhQix9 https://t.co/hb67gLZVuI
-
-
Mashup Score: 5Targeting Lower LDL-C: The Role of Nonstatin Therapies in ASCVD - 1 year(s) ago
While statins are universally recommended as a first-line therapy to reduce the risk of cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD), additional therapies are often needed to help reduce the residual cardiovascular risk. So what role do PCSK9i mAbs like Repatha® (evolocumab) play for patients with ASCVD, and how are they incorporated into the 2022 ACC…
Source: reachmd.comCategories: Expert Picks, Latest HeadlinesTweet-
Need a primer on the new Expert Consensus Decision Pathway Lipid document? Listen to our #ReachMD podcast "Targeting Lower LDL-C: The Role of Nonstatin Therapies in ASCVD" which I co-hosted with @MichaelJBlaha. https://t.co/oq2UufP5DX
-
-
Mashup Score: 0
KEYNOTE-048 has opened new vistas to managing patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Nonetheless, uncertainties remain in matching the correct patient with the correct strategy. Join Drs. Barbara Burtness and Nabil Saba as they parse the key trials and offer insight into building treatment algorithms designed to optimize outcomes for your patients…
Source: reachmd.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Happy to share this CME activity covering Personalizing Treatment of Recurrent/Metastatic HNSCC: A Multifactorial Path https://t.co/6vcZsaBupr via @ReachMD
-
-
Mashup Score: 0Innovations in Oncology - 1 year(s) ago
Innovations in Oncology
Source: reachmd.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
View the NEW Innovations in Oncology Learning Center for CE opportunities. Experts from around the world discuss the latest emerging clinical evidence in the optimal treatment of cancer. Learn more: https://t.co/KQROfDAbrx @ProvaEducation @ReachMD https://t.co/gABLpZuM8d
-
-
Mashup Score: 0Gravity & The Gut: Exploring a Key Hypothesis for IBS - 1 year(s) ago
The pathogenesis of irritable bowel syndrome (IBS) remains unclear, but according to one professor, gravity may play a bigger role in this condition than we think. Dr. Peter Buch sits down with Dr. Brennen Spiegel from the Cedars Sinai Center for Outcomes Research and Education to dive into his research on gravitational management systems and IBS.
Source: reachmd.comCategories: Future of Medicine, Latest HeadlinesTweet-
"Gravity & The Gut: Exploring a Key Hypothesis for #IBS" - In this interview with @ReachMD, I discuss how our body evolved to manage gravity, what can go wrong with the GI tract and beyond if we struggle to manage g-forces, and what we can do about it: https://t.co/SI1uVYEjPS https://t.co/t06i4L8Agu
-
-
Mashup Score: 0Diagnosing NSCLC: A Look at the Complete Picture - 1 year(s) ago
Lung cancer incidence is decreasing due in part to reduced smoking rates, and new trends are emerging as things change. But despite these advancements, some challenges remain to be solved. Explore those challenges and key strategies for overcoming them in this four-part series. PP-US-8201a-1520 12/22
Source: reachmd.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Our new podcast. Lung cancer as the poster child for molecular driven therapies. Diagnosing NSCLC: A Look at the Complete Picture https://t.co/zESrMMSsgi via @ReachMD
-
-
Mashup Score: 0State of the Union on mRNA Clinical Trials - 1 year(s) ago
Clinical data continues to emerge on mRNA therapeutics and their applications. What do we need to know about this data, and are there any barriers to the broader application of these therapeutics? Dr. Charles Turck is joined by Musaddiq Khan, the Vice President of Therapeutic Area Solutions in the Customer Value Team at Medable, to dive into clinical trials for mRNA therapeutics.
Source: reachmd.comCategories: Future of Medicine, Latest HeadlinesTweet-
Listen in! Medable’s Musaddiq Khan joined the @ReachMD podcast to talk about clinical trials for mRNA therapeutics, emerging data trends and barriers to application. Hear the episode now: https://t.co/jbQOutoSo6 ________ #clinicaltrials #clinicalresearch https://t.co/pMIp5DkvcP
-
-
Mashup Score: 0CPPD Epidemiology and Pathogenesis - 2 year(s) ago
What do we need to know about the epidemiology and pathogenesis of calcium pyrophosphate deposition? Dr. Jason Liebowitz is joined by Dr. Sara Tedeschi from Harvard Medical School to share key insights on CPPD. Dr. Liebowitz and Dr. Tedeschi are Novartis consultants 10/22 236268
Source: reachmd.comCategories: Latest Headlines, RheumatologyTweet-
#BWHRheumatology Dr. Sara Tedeschi (@SaraKTedeschi) discusses calcium pyrophosphate deposition disease (#CPPD) epidemiology and pathogenesis on ReachMD's "Living Rheum" podcast. Full interview and transcript linked below: https://t.co/v1cfHh46iL https://t.co/WecNMhyovK
-
-
Mashup Score: 5
New data suggests that the use of anti-TNF therapy early in the treatment course can be effective for patients with inflammatory bowel disease (IBD). However, some of them may still require surgery. But is anti-TNF therapy safe in the perioperative period? To answer this question, Dr. Peter Buch is joined by Drs. Benjamin Cohen and Stefan Holubar from the Cleveland Clinic to discuss the findings…
Source: reachmd.comCategories: Gastroenterology, Latest HeadlinesTweet-
RT @HolubarStefan: #IBD Perioperative Biologic Therapy in @IBDBen & @HolubarStefan https://t.co/6vYgewUg9R @MRegueiroMD @ScottRSteeleMD @SW…
-
Check this out! Dr.@ericka_fink lead author of this study, says the next step is to delve deeper into understanding inflammation markers and other factors that could potentially help predict which patients are at risk for ongoing symptoms. ... https://t.co/93vSJv6suB